US Markets
AZN

AstraZeneca resumes U.S. COVID-19 vaccine trial, optimism seen for J&J

Credit: REUTERS/DADO RUVIC

AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by U.S. regulators, the company said on Friday.

Oct 23 (Reuters) - AstraZeneca Plc AZN.L has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by U.S. regulators, the company said on Friday.

AstraZeneca's U.S. trial was paused on Sept. 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial.

U.S. Health and Human Services Deputy Chief of Staff Paul Mango also told a meeting he was optimistic a U.S. trial by Johnson & Johnson JNJ.N would resume.

(Reporting by Munsif Vengattil and Carl O'Donnell; Editing by Anil D'Silva and Rosalba O'Brien)

((munsif.vengattil@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN JNJ

Latest US Markets Videos

Nasdaq's Essner on OPEC+, Oil Market Outlook

Dec 03, 2021

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More